Aug 06, 2024 / 08:30PM GMT
Operator
(Operator instructions)
Murdo Gordon - Amgen Inc - Executive Vice President - Global Commercial Operations
And Bill sales decreased 15% year over year for the second quarter, primarily driven by lower net selling price. Going forward, we expect continued declining net selling price and relatively flat volumes and roll is known for its efficacy and trusted by physicians. Substantial health benefits and cash flow generation provide a solid foundation for our business.
Turning now to biosimilars were sales of our biosimilar products were relatively stable year over year. For the second quarter, we're positioned for future growth with upcoming launches with Lana biosimilar to Stelara and Mackenzie. A biosimilar to Solaris are both expected to launch in the US into 2025 are vertically integrated biosimilar business model ensures efficiency and provides attractive cash flows and returns for our shareholders.
James Bradner - Amgen Inc - Executive VP of Research and Development & Chief Scientific Officer
Sales of
Q2 2024 Amgen Inc Earnings Call Transcript
Aug 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers